A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of ZVS101e Administered as a Single Monocular Subretinal Injection in Subjects With Bietti's Crystalline Dystrophy (BCD)
Latest Information Update: 30 Aug 2024
At a glance
- Drugs ZVS 101e (Primary)
- Indications Bietti crystalline dystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chigenovo
Most Recent Events
- 28 Aug 2024 Planned primary completion date changed from 1 Dec 2028 to 1 Dec 2024.
- 28 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 02 May 2023 New trial record